BioCentury
ARTICLE | Strategy

Questions of the heart

August 3, 2009 7:00 AM UTC

On its way to becoming a bellwether biotech, Gilead Sciences Inc. saw its market cap jump some 50% in less than two years, climbing from about $26 billion in early 2006 to about $40 billion by October 2007.

Making a similar leap on the back of a new cardiovascular franchise may prove more challenging, if only because the starting point is so much bigger - the company is again valued at about $40 billion in the post-meltdown economy...